Literature DB >> 30670196

Universal Screening for HIV and Hepatitis C Infection: A Community-Based Pilot Project.

Mirjam-Colette Kempf1, Corilyn Ott2, Jenni M Wise2, Alison P Footman3, Brook Y Araya3, Claudia M Hardy4, Cordia Walker4, Charles Latham5, Romeo Stockett5, George Daniels5, Mark Alexander5, Robin G Lanzi3.   

Abstract

INTRODUCTION: Black men in the Deep South have been disproportionally affected by high HIV and hepatitis C virus infection rates. Conventional clinic-based screening approaches have had limited success in reaching those with undiagnosed HIV or hepatitis C virus infection. The purpose of this study was to evaluate the acceptability, feasibility, and best practices of an integrated HIV and hepatitis C virus community-based health screening approach.
METHODS: The study used a mixed methods approach: focus group discussion, individual interviews, and surveys that assessed perceptions, perspectives, and HIV and hepatitis C virus awareness among six communities across Alabama and Mississippi. Data were collected and analyzed in 2014-2017.
RESULTS: Although HIV and hepatitis C virus knowledge was limited among community members surveyed, the results of this study suggest that (1) using an integrated, community-based HIV and hepatitis C virus testing approach is acceptable and feasible; (2) formation of a community advisory board is a key element of successful community mobilization; (3) education and training of community members on disease-specific topics and overcoming stigma are essential; and (4) focus on and inclusion of young community members will be critical for the sustainability of screening efforts.
CONCLUSIONS: Including and engaging communities at risk for HIV and hepatitis C virus infection in prevention research is a promising strategy to overcome existing barriers of stigma and discrimination. Integration of HIV and hepatitis C virus testing in universal health screening efforts utilizing a Community Health Advisors model encourages unbiased communication with a focus on overall community health. Community health advisors are recognized as important agents in this effort. SUPPLEMENT INFORMATION: This article is part of a supplement entitled African American Men's Health: Research, Practice, and Policy Implications, which is sponsored by the National Institutes of Health.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30670196      PMCID: PMC6548448          DOI: 10.1016/j.amepre.2018.05.015

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  32 in total

1.  Laying the foundation for Connect to Protect: a multi-site community mobilization intervention to reduce HIV/AIDS incidence and prevalence among urban youth.

Authors:  Mauri A Ziff; Gary W Harper; Kate S Chutuape; Bethany Griffin Deeds; Donna Futterman; Vincent T Francisco; Larry R Muenz; Jonathan M Ellen
Journal:  J Urban Health       Date:  2006-05       Impact factor: 3.671

2.  Differences between proof-of-concept studies and effective implementation: routine, opt-out HIV testing in emergency departments.

Authors:  Mary Jane Rotheram-Borus; Lee E Klosinski; Mark A Etzel
Journal:  J Acquir Immune Defic Syndr       Date:  2007-12-01       Impact factor: 3.731

3.  Community-Based Participatory Research Studies on HIV/AIDS Prevention, 2005-2014.

Authors:  Steven S Coughlin
Journal:  Jacobs J Community Med       Date:  2016-01-06

4.  Community-based participatory research: a new and not-so-new approach to HIV/AIDS prevention, care, and treatment.

Authors:  Scott D Rhodes; Robert M Malow; Christine Jolly
Journal:  AIDS Educ Prev       Date:  2010-06

5.  Project GRACE: a staged approach to development of a community-academic partnership to address HIV in rural African American communities.

Authors:  Giselle Corbie-Smith; Adaora A Adimora; Selena Youmans; Melvin Muhammad; Connie Blumenthal; Arlinda Ellison; Aletha Akers; Barbara Council; Yolanda Thigpen; Mysha Wynn; Stacey W Lloyd
Journal:  Health Promot Pract       Date:  2010-08-04

6.  The Deep South Network for cancer control. Building a community infrastructure to reduce cancer health disparities.

Authors:  Nedra Lisovicz; Rhoda E Johnson; John Higginbotham; Jennifer A Downey; Claudia M Hardy; Mona N Fouad; Agnes W Hinton; Edward E Partridge
Journal:  Cancer       Date:  2006-10-15       Impact factor: 6.860

7.  Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; John W Ward
Journal:  Ann Intern Med       Date:  2012-12-04       Impact factor: 25.391

8.  Late HIV testing - 34 states, 1996-2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-06-26       Impact factor: 17.586

9.  Continuum of Care for Hepatitis C Virus Among Patients Diagnosed in the Emergency Department Setting.

Authors:  Erik S Anderson; James W Galbraith; Laura J Deering; Sarah K Pfeil; Tamara Todorovic; Joel B Rodgers; Jordan M Forsythe; Ricardo Franco; Henry Wang; N Ewen Wang; Douglas A E White
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

10.  Late diagnosis and entry to care after diagnosis of human immunodeficiency virus infection: a country comparison.

Authors:  H Irene Hall; Jessica Halverson; David P Wilson; Barbara Suligoi; Mercedes Diez; Stéphane Le Vu; Tian Tang; Ann McDonald; Laura Camoni; Caroline Semaille; Chris Archibald
Journal:  PLoS One       Date:  2013-11-05       Impact factor: 3.240

View more
  2 in total

1.  CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.

Authors:  Sarah Schillie; Carolyn Wester; Melissa Osborne; Laura Wesolowski; A Blythe Ryerson
Journal:  MMWR Recomm Rep       Date:  2020-04-10

Review 2.  Mitochondrial changes associated with viral infectious diseases in the paediatric population.

Authors:  Sonia Romero-Cordero; Antoni Noguera-Julian; Francesc Cardellach; Clàudia Fortuny; Constanza Morén
Journal:  Rev Med Virol       Date:  2021-03-31       Impact factor: 11.043

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.